SCHEMBL5340796

SCHEMBL5340796

COc1ccc(C(=O)Nc2ccc3sc(C)nc3c2Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
KDM4E B2RXH2 3/20 0.52
HPGD P15428 2/20 0.52
PPARG P37231 1/20 0.52
PTK2B Q14289 1/20 0.52
NCOA2 Q15596 1/20 0.52
NCOA1 Q15788 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NR2E3 Q9Y5X4 1/20 0.52
NCOR2 Q9Y618 1/20 0.52
NCOA3 Q9Y6Q9 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 1/20 0.51
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 3/20 0.50
DUSP3 P51452 3/20 0.50
F10 P00742 2/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5338394 0.87 MAPT (0.55) RAB9ANPC1KDM4EHPGDSMN1; SMN2
SCHEMBL14484090 0.84 RAB9A (0.53) RAB9ANPC1KDM4EHPGDNPSR1
SCHEMBL5333962 0.83 LMNA (0.53) RAB9AKDM4ESMN1; SMN2TP53MEN1
SCHEMBL5337736 0.82 HSD11B1 (0.51) RAB9ANPC1KDM4EHPGDSMN1; SMN2
SCHEMBL5334463 0.82 GAA (0.45) RAB9ANPC1KDM4EHPGDMEN1
SCHEMBL5337496 0.76 MAPT (0.58) RAB9ASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL5340071 0.74 HSD11B1 (0.59) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL5122545 0.74 TRPV1 (0.63) NPC1KDM4ENPSR1SMN1; SMN2DUSP3
SCHEMBL5121887 0.74 TRPV1 (0.64) RAB9ANPC1KDM4ESMN1; SMN2TP53
SCHEMBL3794444 0.74 F10 (0.76) RAB9ANPC1NPSR1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US claimed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
US-7230020-B2 11β-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2007-06-12 US disclosed
EP-1675844-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE Sterix Limited (GB) 2006-07-05 EP disclosed
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors STERIX LIMITED (GB) 2005-10-13 US disclosed
WO-2005042513-A1 PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE STERIX LIMITED (GB) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227987-A1 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD17B3 RAB9A 3856/4885NPC1 1239/4885KDM4E 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.